Position in LYEL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$2,507
-$1,340 QoQ
Shares Held
125
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026WELLS FARGO & COMPANY/MN holds $1,292,861,286 across 390 Biotechnology names. LYEL ranks #320 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
744,995 | $332,670,066 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
342,763 | $113,409,991 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
142,021 | $109,731,102 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,535,737 | $99,254,679 | |
| 5 | INSM |
INSMED Inc
|
597,384 | $97,684,229 | |
| 6 | ASND |
Ascendis Pharma A/S
|
154,199 | $35,269,936 | |
| 7 | EXEL |
Exelixis, Inc.
|
687,304 | $29,478,466 | |
| 8 | ARGX |
Argenx SE
|
38,104 | $27,825,444 |
All Filings in LYEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,507 | 125 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $3,847 | 125 | Shares | Defined | 2026-02-13 | |
| 2025-06-30 | $17,414 | 1,970 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||